6.4 Dietary Supplement & Herbal Safety during Cancer Therapy

Dietary Supplement & Herbal Safety during Cancer Therapy

Dietary supplements and botanical products are widely utilized by oncology patients, often under the false assumption that 'natural' products are inherently safe and free of side effects. In reality, bioactive plant constituents act as potent pharmacologic agents—functioning as hepatic enzyme inducers, enzyme inhibitors, drug transporter antagonists, or antiplatelet agents. Board Certified Specialists in Oncology Nutrition (CSOs) play a critical patient-safety role by conducting rigorous supplement reconciliations to identify, educate, and eliminate high-risk interactions during systemic chemotherapy, targeted therapy, radiation, and surgery.

---

Regulatory Context: DSHEA of 1994

Under the Dietary Supplement Health and Education Act (DSHEA) of 1994, dietary supplements are regulated as food products rather than pharmaceuticals. Consequently, supplement manufacturers are not required to demonstrate safety or efficacy prior to marketing. This regulatory structure results in key clinical vulnerabilities:

• Lack of Standardization: Active constituent concentrations vary dramatically between product batches and brands.
• Adulteration & Contamination: Unlisted compounds, heavy metals (lead, arsenic), or undeclared pharmaceutical ingredients are periodically detected in commercial herbal products.
• Unsubstantiated Marketing: Structure/function claims often mislead patients regarding cancer-fighting properties.

---

High-Risk Botanical Interactions with Systemic Therapies

St. John's Wort (Hypericum perforatum)

St. John's Wort is widely used for mild depression but represents one of the most dangerous botanical supplements in oncology. Its primary active constituent, hyperforin, functions as a potent high-affinity ligand for the Pregnane X Receptor (PXR) in human hepatocytes and intestinal enterocytes.

[Hyperforin in St. John's Wort] ──► [Binds & Activates Pregnane X Receptor (PXR)]
                                            │
                                            ▼
[Transcriptional Induction of Hepatic CYP3A4 & P-gp Efflux Pumps]
                                            │
                                            ▼
[Accelerated Degradation & Clearance of Chemotherapy Drugs]
                                            │
                                            ▼
[Subtherapeutic Plasma Drug Concentrations ➔ Treatment Failure & Tumor Progression]

• Pharmacokinetic Mechanism: Activation of PXR triggers transcriptional upregulation of Cytochrome P450 3A4 (CYP3A4) enzymes and P-glycoprotein (P-gp / ABCB1) efflux pumps.
• Impact on Irinotecan: St. John's Wort increases clearance of irinotecan's active metabolite (SN-38) by 42%, dropping circulating plasma drug concentrations far below therapeutic antineoplastic thresholds.
• Impact on Other Agents: Significantly reduces plasma AUC for imatinib, tamoxifen, docetaxel, paclitaxel, cyclophosphamide, etoposide, and tyrosine kinase inhibitors (TKIs), leading to disease progression and treatment failure.

Green Tea Extract & Concentrated EGCG (Camellia sinensis)

While consuming moderate amounts of brewed green tea is generally safe, high-dose concentrated Green Tea Extract supplements containing high levels of epigallocatechin gallate (EGCG) pose a severe threat to patients receiving bortezomib (Velcade) or ixazomib (Ninlaro) for multiple myeloma or mantle cell lymphoma.

• Molecular Mechanism: EGCG possesses a vicinal diol (catechol) functional group that directly forms a covalent chemical bond with the boronic acid group on the bortezomib molecule.
• Clinical Result: This chemical binding completely blocks bortezomib from engaging its intracellular target (the 20S proteasome), neutralizing bortezomib-induced apoptosis in myeloma cells and causing total therapeutic failure.

---

High-Risk Botanical & Supplement Summary Matrix

---

The '4 Gs' and Perioperative / Bleeding Risks

The botanical supplements Garlic (high-dose extracts/oils), Ginkgo biloba, Ginseng, and Ginger (concentrated supplements) are known collectively in clinical oncology as the '4 Gs'.

Mechanisms of Antiplatelet Action

• Ginkgo Biloba: Acts as a potent antagonist to Platelet-Activating Factor (PAF) receptors.
• Garlic (Allicin/Ajoene): Inhibits cyclooxygenase and thromboxane synthesis, reducing platelet aggregation.
• Ginseng (Ginsenosides): Inhibits thromboxane A2 formation and platelet adhesion.
• Ginger (Gingerols/Shogaols): Inhibits COX-1 and thromboxane synthetase.

Clinical Management Guidelines

1. Preoperative Discontinuation: All '4 G' supplements must be strictly discontinued at least 2 to 3 weeks prior to any planned surgical procedure, tumor resection, or invasive tissue biopsy to prevent severe perioperative hemorrhage.
2. Thrombocytopenia Safety: Patients experiencing chemotherapy-induced thrombocytopenia (platelet count <50,000/µL) must avoid all '4 G' supplements to prevent spontaneous mucosal bleeding, epistaxis, or gastrointestinal hemorrhage.

---

High-Dose Antioxidant Supplements During Pro-Oxidant Therapies

Many conventional cancer modalities—including radiation therapy and cytotoxic chemotherapies such as doxorubicin (Adriamycin), bleomycin, cisplatin, and alkylating agents—exert their therapeutic effect by generating massive intracellular Reactive Oxygen Species (ROS) (hydroxyl radicals $\cdot OH$, superoxide $\text{O}_2^{\cdot-}$).

$\text{Radiation / Doxorubicin} \longrightarrow \text{Reactive Oxygen Species (ROS)} \longrightarrow \text{Double-Stranded DNA Breaks} \longrightarrow \text{Apoptosis}$

These ROS induce single- and double-stranded DNA breaks ($\gamma$-H2AX foci formation), triggering p53-mediated apoptosis in rapidly dividing malignant cells.

[Radiation / Pro-Oxidant Chemotherapy (Doxorubicin, Bleomycin)]
                     │
                     ▼
[Generation of Cytotoxic Reactive Oxygen Species (ROS)]
                     │
                     ▼
[Induction of Cancer Cell DNA Breaks & Apoptosis]
                     │  ◄─── ❌ High-Dose Antioxidants (Vit C >1000mg, Vit E >400IU)
                     │       Scavenge Free Radicals & Protect Tumor Cells
                     ▼
[Blunted Treatment Efficacy & Enhanced Tumor Survival]

Mechanisms of Antioxidant Interference

When patients ingest high-dose isolated antioxidant supplements—such as Vitamin C (>1000 mg/day), Vitamin E (>400 IU/day), N-acetylcysteine (NAC), or Coenzyme Q10—these antioxidants donate electrons to neutralize ROS before DNA damage can occur. By scavenging therapeutic free radicals, high-dose isolated antioxidants protect cancer cells from treatment-induced apoptosis, blunting overall therapeutic efficacy.

CSO Clinical Recommendations on Antioxidant Intake

• Prohibit High-Dose Supplements: Instruct patients to discontinue isolated high-dose antioxidant supplements during active radiation therapy or pro-oxidant chemotherapy.
• Promote Whole Foods: Reassure patients that consuming antioxidant-rich whole fruits, vegetables, berries, green leafy vegetables, and nuts is entirely safe and encouraged. The natural food matrix concentrations do not interfere with cytotoxic treatment and provide essential phytonutrients.